Novel heuristics for cell radius determination in WCDMA systems and their application to strategic planning studies

We propose and compare three novel heuristics for the calculation of the optimal cell radius in mobile networks based on Wideband Code Division Multiple Access (WCDMA) technology. The proposed heuristics solve the problem of the load assignment and cellular radius calculation. We have tested our approaches with experiments in multiservices scenarios showing that the proposed heuristics maximize the cell radius, providing the optimum load factor assignment. The main application of these algorithms is strategic planning studies, where an estimation of the number of Nodes B of the mobile operator, at a national level, is required for economic analysis. In this case due to the large number of different scenarios considered (cities, towns, and open areas) other methods than simulation need to be considered. As far as we know, there is no other similar method in the literature and therefore these heuristics may represent a novelty in strategic network planning studies. The proposed heuristics are implemented in a strategic planning software tool and an example of their application for a case in Spain is presented. The proposed heuristics are used for telecommunications regulatory studies in several countries

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective